GLP Watchdog

Mochi Health vs Wisp

Neither Mochi Health nor Wisp has an FDA warning letter on record. On compounded oral semaglutide, Mochi Health costs $1,008 less a year at standing rates: $141 a month against $225 a month at Wisp.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Mochi Health / Wisp

Mochi Health logo

Mochi Health

7.1/10

Wisp logo

Wisp

7.1/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$110/moFoundayo (orforglipron) pill
$225/moCompounded oral semaglutide
States
All 50 states
39 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026
Visit Mochi Health
Visit Wisp

Neither Mochi Health nor Wisp pays us. Links to them earn nothing. Scores: Mochi Health 7.1, Wisp 7.1. How we are paid

What the record shows

  1. 01

    Neither Mochi Health nor Wisp has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On compounded oral semaglutide, Mochi Health costs $1,008 less a year at standing rates: $141 a month against $225 a month at Wisp.

  4. 04

    Only Mochi Health lists a price for compounded semaglutide injection, compounded tirzepatide injection and brand-name semaglutide pen.

  5. 05

    Mochi Health covers 11 states Wisp does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Mochi Health

Wisp

Compounded oral semaglutide

$141/moLower

$1,692 a year

$225/mo

$2,700 a year

Compounded semaglutide injection

$139/mo

plan terms unclear; not compared

Not sold or not priced
Compounded tirzepatide injection

$169/mo

plan terms unclear; not compared

Not sold or not priced
Brand-name semaglutide pen

$199/mo

medication only, membership extra; not compared

Not sold or not priced
Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Brand-name semaglutide pill

$149/mo

medication only, membership extra; not compared

Not sold or not priced
Foundayo (orforglipron) pill

$110/mo

$1,320 a year

Not sold or not priced
Price includes
Clinician visits, coaching
Medication, shipping
Billed separately
Medication
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly plan; 3, 6 and 12-month memberships are prepaid
Not stated
Refunds
No refunds for partly used periods; medication is not refundable once sent to the pharmacy
All sales are final

Read off each seller’s own pages. Mochi Health: October 31, 2026. Wisp: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Mochi Health

7.1/10
  • $1,008 a year less on compounded oral semaglutide
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Wisp does not price
  • Lists 50 states against 39
  • Names no compounding pharmacy
  • Price leaves out medication
Visit Mochi Health

The case for Wisp

7.1/10

The record gives Wisp no edge on this pair.

  • Names no compounding pharmacy
Visit Wisp

Scores

Mochi Health 7.1 · Wisp 7.1 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
4.1

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

7.5A
vs
B
8.0

Trust & Safety15%

8.5A
vs
B
7.5

Accessibility10%

10.0A
vs
B
8.2

Support10%

4.0A
vs
B
4.5

The score is the same formula for every seller. Payment does not enter it. Method

Mochi Health vs Wisp: questions

Neither Mochi Health nor Wisp has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Mochi Health, by $1,008 a year at standing rates. Mochi Health: $141 a month, about $1,692 a year. Wisp: $225 a month, about $2,700 a year.
Mochi Health states you can cancel at any time; refunds: no refunds for partly used periods; medication is not refundable once sent to the pharmacy. Wisp states you can cancel at any time; refunds: all sales are final.
Neither Mochi Health nor Wisp pays us. Links to them earn nothing. Scores: Mochi Health 7.1, Wisp 7.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks